Analysis of childhood and adolescent melanocytic lesions
Official title: Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Run by St. Jude Children's Research Hospital · NCT02775643 · Data updated 2026-11-12
This study is looking to see how genetic changes in kids and teens with skin lesions, including melanoma, affect their treatment and outcomes, using information collected during their regular medical care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | May 31, 2016 |
| Main results expected | May 31, 2031 |
| Study ends | May 31, 2041 |
| Registry record updated | November 10, 2025 |
| Trial ID | NCT02775643 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pediatric patients under 19 years old with a suspected or confirmed diagnosis of specific melanocytic lesions.
✕Probably not a fit
Patients with ocular melanoma or those unwilling to consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect clinical and molecular information from pediatric patients diagnosed with melanocytic lesions, including various types of melanoma. Researchers will analyze DNA and RNA from tumor and blood cells to identify genetic changes associated with tumor development and treatment response. The study will also gather information on treatments received and their effectiveness, without requiring additional procedures beyond standard medical care. Tumor samples will be obtained as part of routine diagnosis, and a small amount of blood will be collected for analysis.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pediatric melanoma and improve treatment strategies for affected patients.
How similar studies have gone: Other studies have shown success in analyzing genetic changes in tumors, making this approach promising but still focused on a specific pediatric population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant has a suspected or confirmed diagnosis of a melanocytic lesion, including: * Conventional or "adult-type" melanoma * Spitzoid melanoma/atypical Spitz tumor * Congenital melanoma * Melanoma arising in a giant congenital nevus * Melanocytic lesions with indeterminate biological behavior (e.g., pigment synthesizing melanomas) * Participant was \<19 years of age at the time of diagnosis. * Tissue is available for biologic studies. * Participant has been enrolled on the TBANK protocol at SJCRH, or will be enrolled before any research tests are performed on their biological materials. Exclusion Criteria: * Ocular melanoma * Inability or unwillingness of research participant or legal guardian to consent. * Histologic diagnosis other than melanocytic lesion described in 3.1.1.
Where it's running
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Alberto Pappo, MD — St. Jude Children's Research Hospital
- Study coordinator: Alberto Pappo, MD
- Email: referralinfo@stjude.org
- Phone: 866-278-5835
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.